Qingdao Vland Biotech Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 7.33%

Qingdao Vland Biotech Co Ltd (603739) has an Asset Resilience Ratio of 7.33% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥223.10 Million

≈ $32.65 Million USD Cash + Short-term Investments

Total Assets

CN¥3.04 Billion

≈ $445.07 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Qingdao Vland Biotech Co Ltd's Asset Resilience Ratio has changed over time. Check Qingdao Vland Biotech Co Ltd (603739) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Qingdao Vland Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Qingdao Vland Biotech Co Ltd worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥223.10 Million	7.33%
Total Liquid Assets	CN¥223.10 Million	7.33%

Asset Resilience Insights

Limited Liquidity: Qingdao Vland Biotech Co Ltd maintains only 7.33% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Qingdao Vland Biotech Co Ltd Industry Peers by Asset Resilience Ratio

Compare Qingdao Vland Biotech Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Prostemics Co. Ltd KQ:203690	Biotechnology	0.31%
ORUM KQ:475830	Biotechnology	82.74%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
TG Therapeutics Inc NASDAQ:TGTX	Biotechnology	4.72%
Green Cross Holdings Preference Shares KO:005257	Biotechnology	0.50%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	33.70%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Cybin Inc NEO:CYBN	Biotechnology	0.21%

Annual Asset Resilience Ratio for Qingdao Vland Biotech Co Ltd (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Qingdao Vland Biotech Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	6.69%	CN¥199.34 Million ≈ $29.17 Million	CN¥2.98 Billion ≈ $436.21 Million	-2.94pp
2023-12-31	9.63%	CN¥292.05 Million ≈ $42.74 Million	CN¥3.03 Billion ≈ $443.98 Million	+1.40pp
2022-12-31	8.22%	CN¥212.02 Million ≈ $31.03 Million	CN¥2.58 Billion ≈ $377.37 Million	+0.55pp
2021-12-31	7.67%	CN¥170.43 Million ≈ $24.94 Million	CN¥2.22 Billion ≈ $325.11 Million	+0.96pp
2020-12-31	6.71%	CN¥97.45 Million ≈ $14.26 Million	CN¥1.45 Billion ≈ $212.40 Million	-7.56pp
2019-12-31	14.28%	CN¥182.90 Million ≈ $26.76 Million	CN¥1.28 Billion ≈ $187.49 Million	--

pp = percentage points

About Qingdao Vland Biotech Co Ltd

SHG:603739 China Biotechnology

Market Cap

$430.61 Million

CN¥2.94 Billion CNY

Market Cap Rank

#13010 Global

#3835 in China

Share Price

CN¥11.63

Change (1 day)

+1.04%

52-Week Range

CN¥10.81 - CN¥16.74

All Time High

CN¥58.91